摘要
目的探讨西格列汀与二甲双胍早期联合治疗对初诊Ⅱ型糖尿病患者长期缓解率的影响。方法选取2013年1月至2014年1月接受治疗的初诊Ⅱ型糖尿病患者200例，随机分为单药治疗组和联合治疗组，每组各100例。单药治疗组予二甲双胍治疗，联合治疗组在二甲双胍基础上加西格列汀片，治疗疗程24周，分别检测两组患者治疗前后空腹血糖（FBG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbAlc）、血脂、胰岛素原与胰岛素比值（PI／IR）。治疗24周后，血糖达标的患者停药观察，比较停药1年后两组患者长期缓解率的差异。结果治疗24周后，两组患者FBG、2hPG、HbAlc、PI／IR血脂与基线相比下降，联合治疗组下降更明显，联合治疗组血糖达标时间短、达标率更高。差异有统计学意义（P〈0．01）。1年后联合治疗组长期缓解率（37．23％）显著高于单药治疗组（9．78％）（P〈0．01），不良反应发生率未增加（P〉0．05）。结论对新诊断的Ⅱ型糖尿病患者，二甲双胍与西格列汀早期联合治疗较单药二甲双胍起始治疗可以更有效地控制血糖、改善胰岛B细胞功能，使更多患者获得长期缓解，未增加不良反应发生率，可作为初发Ⅱ型糖尿病患者治疗的理想选择。
Objective To investigate the influence of long-term remission rate on early combined treatment of sitagliptin and metformin in newly diagnosed type 2 diabetes. Methods 200 patients with newly diagnosed type 2 diabetes were enrolled in the study who were admitted into the First Peaple＇ s Hospital of Yuhang District, Hang zhou, Zhe jiang from June 2013 to June 2014. The subjects were divided into two groups： Combination group （ n=100 ） and Monotherapy group （ n=100 ） . The Monotherapy group was administrated with metformin tablets, and the Combination group was treated by metformin tablets with sitagliptin tablets. The treatment duration was 24 week for both groups. Comparison was made between the two groups in changes of FBG, 2hPG, HBA1C, hematic fat, PI/IR before and after treatment. The long-term remission rate of two groups after drugs stopped one year was also compared. Results After treatment, FBG, 2hPG, HBA1C, hematic fat, PI/IR were decreased significantly compared with baseline. （ P〈0.05 ） and decreased more significantly in Combination group （ P〈0.05 ）. The time of re＇aching the expected blood sugar levels and treatment qualification rate were higher in Combination group than that in the Monotherapy group, the difference was statistically significant. （ P〈0.01 ） . After antidiabetic drugs stopped one year, long-term remission rate of Combination group （ 37.23% ） was obviously higher than that of Monotherapy group （ 9.78% ） , （ P〈0.01 ） . And the incidence of adverse reaction rate did not increase compared with the Monotherapy group. Conclusion Early combined treatment of Sitagliptin and Mefformin in newly diagnosed type 2 diabete can contol blood sugar, improve the pancreas islet function more effectively, and can get higher long-term remission rate. The strategy can be employed in newly diagnosed type 2 diabetes.
出处
《浙江临床医学》
2017年第6期997-999,共3页
Zhejiang Clinical Medical Journal
基金
杭州市余杭区科学技术局基金项目（2013012）
关键词
糖尿病
Ⅱ型
长期缓解
西格列汀
二甲双胍
Diabetes mellitus, Type 2 Long-term remission Sitagliptin Metformin
